4.2 Article

Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers

期刊

INTERNAL MEDICINE
卷 55, 期 9, 页码 1183-1186

出版社

JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.55.5319

关键词

non-producing multiple myeloma; quadruple cancer; autopsy

向作者/读者索取更多资源

We report the case of a 72-year-old man who presented with non-producing multiple myeloma ( MM) with three additional concomitant solid tumors that were identified by postmortem autopsy. The disease was refractory to anti-MM therapy including bortezomib and lenalidomide, and he finally died of bacterial pneumonia with diffuse alveolar damage 8 months after the diagnosis. An autopsy revealed that he was also affected by three other solid cancers, cholangiocellular carcinoma, medullary thyroid cancer and papillary thyroid cancer that were clinically asymptomatic and remained undiagnosed before death. A review of the literature suggests that primary quadruple cancers including MM are extremely rare.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)

Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, Noriko Fukuhara, Sachiko Seo, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura, Akira Hangaishi, Takahiro Yamauchi, Takahiko Utsumi, Ishikazu Mizuno, Yasushi Takamatsu, Yasuyuki Nagata, Koichiro Minauchi, Eiichi Ohtsuka, Ichiro Hanamura, Shinichiro Yoshida, Satoshi Yamasaki, Youko Suehiro, Yutaro Kamiyama, Kunihiro Tsukasaki, Hirokazu Nagai

Summary: A randomised phase II study was conducted to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) in transplant-ineligible untreated multiple myeloma patients. The study suggested that Arm A was the more promising regimen, with the twice weekly schedule of bortezomib in the first cycle and higher cumulative dose of both bortezomib and melphalan influencing the efficacy of modified MPB. Frequent grade ≥3 haematologic toxicities in Arms A and B were neutropenia and thrombocytopenia. Grade 2/3 peripheral neuropathy was also observed, more so in Arm A than Arm B.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Article Pathology

Mantle cell lymphoma with EBV-positive Hodgkin and Reed-Sternberg-like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors

Risa Kanai, Aya Miyagawa-Hayashino, Yukiko Shishido-Hara, Naoya Nakamura, Ikoi Omatsu, Yukiko Morinaga, Yuji Shimura, Junya Kuroda, Tetsuya Imura, Kyoko Itoh, Eiichi Konishi

Summary: The case report describes a 70-year-old man with mantle cell lymphoma (MCL) who relapsed as a combination of MCL and classic Hodgkin lymphoma (cHL) 9 years after autologous peripheral blood stem cell transplant. The two components were phenotypically distinct but genetically related, indicating a possible transformation of MCL to HRS-like cells with EBV infection. The patient died of disease progression with elevated hepatobiliary enzymes.

PATHOLOGY INTERNATIONAL (2021)

Article Hematology

Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis

Teruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Aya Nakaya, Shin-ichi Fuchida, Hirohiko Shibayama, Mitsuhiro Matsuda, Yutaka Shimazu, Yoko Adachi, Satoru Kosugi, Hitoji Uchiyama, Hirokazu Tanaka, Hitoshi Hanamoto, Yuji Shimura, Junya Kanda, Yoshiyuki Onda, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura

Summary: The study investigated real-world data of IRd therapy for RRMM patients, with a median age of 72 and most patients having IgG type. The median number of prior therapies was 4, mainly comprising bortezomib and lenalidomide-based regimens. Disease progression and adverse events were common reasons for treatment discontinuation. The study found that lenalidomide-refractory patients had significantly lower PFS than lenalidomide-sensitive patients, and the patients with IgG type had significantly better PFS and OS. Overall, IRd showed poor efficacy in non-IgG type and lenalidomide-refractory patients with RRMM in real clinical practice.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Article Oncology

Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma

Teruhito Takakuwa, Kensuke Ohta, Eiji Nakatani, Tomoki Ito, Hitomi Kaneko, Shin-Ichi Fuchida, Yuji Shimura, Hideo Yagi, Hirohiko Shibayama, Junya Kanda, Hitoji Uchiyama, Satoru Kosugi, Hirokazu Tanaka, Eri Kawata, Nobuhiko Uoshima, Jun Ishikawa, Masaru Shibano, Takahiro Karasuno, Maki Shindo, Yoshifumi Shimizu, Kazunori Imada, Yuzuru Kanakura, Junya Kuroda, Masayuki Hino, Shosaku Nomura, Akifumi Takaori-Kondo, Chihiro Shimazaki, Itaru Matsumura

Summary: The plateau phase during the treatment of multiple myeloma (MM) is associated with treatment outcomes, and starting treatment during the plateau phase is linked to better results. The study found that Disease stability index (DSI) is an independent prognostic factor for the treatment with LEN in previously treated MM patients.

HEMATOLOGICAL ONCOLOGY (2021)

Article Medicine, General & Internal

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma

Haruya Okamoto, Nobuhiko Uoshima, Ayako Muramatsu, Reiko Isa, Takahiro Fujino, Yayoi Matsumura-Kimoto, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Eri Kawata, Hitoji Uchiyama, Junya Kuroda

Summary: Bone marrow involvement is associated with prognosis in patients with diffuse large B-cell lymphoma, and the combination of bone marrow biopsy and flow cytometry is the central prognostically relevant approach for its detection. Other bone marrow examinations may also provide complementary information in clinical settings.

DIAGNOSTICS (2021)

Letter Hematology

Expression of activated B-cell gene signature is predictive of the outcome of follicular lymphoma

Taku Tsukamoto, Yuichi Tokuda, Masakazu Nakano, Kei Tashiro, Junya Kuroda

BLOOD ADVANCES (2022)

Article Biochemistry & Molecular Biology

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai, Junya Kuroda

Summary: This study investigated the therapeutic efficacy and mechanism of action of dual blockade of two major PDPK1 substrates, RSK2 and AKT, in multiple myeloma (MM). The combination of inhibitors for RSK2 and AKT showed additive to synergistic anti-tumor effects in MM-derived cell lines with active RSK2 and AKT, and exerted robust molecular effects on critical gene sets associated with myeloma pathophysiologies. These results provide a rationale for the dual-targeting strategy for RSK2 and AKT in overcoming the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Biochemistry & Molecular Biology

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia

Seiichiro Katagiri, SungGi Chi, Yosuke Minami, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi, Takanobu Morishita, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Junya Kuroda, Kensuke Usuki, Daigo Akahane, Akihiko Gotoh

Summary: This paper discusses the role of KIT mutations and the potential of precision medicine in acute myeloid leukemia (AML). New therapies targeting KIT mutations show promise as effective treatments for AML.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Letter Oncology

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

Dai Maruyama, Shinsuke Iida, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura, Kensuke Usuki, Takahiro Yamauchi, Takahiko Utsumi, Ishikazu Mizuno, Yasushi Takamatsu, Yasuyuki Nagata, Shuichi Ota, Eiichi Ohtsuka, Ichiro Hanamura, Yasuhiro Suzuki, Shinichiro Yoshida, Satoshi Yamasaki, Youko Suehiro, Yutaro Kamiyama, Suguru Fukuhara, Kunihiro Tsukasaki, Hirokazu Nagai

CANCER SCIENCE (2022)

Article Oncology

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort

Masaki Ri, Kenshi Suzuki, Tadao Ishida, Junya Kuroda, Taku Tsukamoto, Takanori Teshima, Hideki Goto, Carolyn C. Jackson, Huabin Sun, Lida Pacaud, Ei Fujikawa, Tzu-Min Yeh, Tomoyoshi Hatayama, Kensuke Aida, Yoshihiro Sunagawa, Shinsuke Iida

Summary: CAR-T cell therapy has shown positive responses in patients with relapsed/refractory MM, especially in Japanese patients. The CARTITUDE-1 study demonstrated that cilta-cel has a positive efficacy and safety profile for heavily pretreated MM patients.

CANCER SCIENCE (2022)

Letter Hematology

Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma

Yu Inoue, Koichi Hirakawa, Hiroki Hayata, Daichi Nishiyama, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Junya Kuroda

ANNALS OF HEMATOLOGY (2023)

Article Oncology

Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia

Satoshi Wakita, Atsushi Marumo, Kaoru Morita, Shinichi Kako, Takashi Toya, Yuho Najima, Noriko Doki, Junya Kanda, Junya Kuroda, Shinichiro Mori, Atsushi Satake, Kensuke Usuki, Toshimitsu Ueki, Nobuhiko Uoshima, Yutaka Kobayashi, Eri Kawata, Kazutaka Nakayama, Yuhei Nagao, Katsuhiro Shono, Motoharu Shibusawa, Jiro Tadokoro, Masao Hagihara, Hitoji Uchiyama, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Hisao Nagoshi, Tatsuo Ichinohe, Saiko Kurosawa, Sayuri Motomura, Akiko Hashimoto, Hideharu Muto, Eriko Sato, Masao Ogata, Kenjiro Mitsuhashi, Jun Ando, Haruko Tashiro, Masahiro Sakaguchi, Shunsuke Yui, Kunihito Arai, Tomoaki Kitano, Miho Miyata, Haruka Arai, Masayuki Kanda, Kako Itabashi, Takahiro Fukuda, Yoshinobu Kanda, Hiroki Yamaguchi

Summary: Nucleophosmin1 (NPM1) mutations are common in acute myeloid leukemia (AML) and have been considered as a favorable prognostic factor. However, our analysis of 605 Japanese AML patients, including 174 with NPM1-mutated AML, showed that NPM1 mutations were not associated with better overall survival (OS). Instead, mutations in the DNMT3A gene (DNMT3A(R882) mutations) were found to be a strong predictor of poor prognosis in all AML cases and NPM1-mutated AML cases. The presence of DNMT3A(R882) mutations, as well as the co-occurrence of FLT3-ITD, NPM1, and DNMT3A(R882) mutations (triple mutations), were independent factors associated with worse OS.

CANCER SCIENCE (2023)

Article Hematology

Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma

Kentaro Mizuhara, Yuji Shimura, Taku Tsukamoto, Akinori Kanai, Saeko Kuwahara-Ota, Junko Yamaguchi, Ayako Muramatsu, Haruya Okamoto, Yoko Taminishi-Katsuragawa, Yuka Kawaji-Kanayama, Reiko Isa, Shinsuke Mizutani, Toshiya Inaba, Junya Kuroda

Summary: In multiple myeloma, the shift of the tumour immune microenvironment to a suppressive state promotes disease development and resistance to immunotherapy. This study demonstrates that miR-106a-5p and miR-146a-5p delivered by tumour-derived exosomes play essential roles in inducing monocyte-derived suppressor cells in multiple myeloma. These miRNAs collaborate with CCL5 and MIF to promote the induction of suppressor cells. This finding may contribute to the development of novel therapeutic approaches to improve the efficacy of immunotherapy.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Hematology

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

Yuji Shimura, Hirohiko Shibayama, Aya Nakaya, Ryosuke Yamamura, Kazunori Imada, Hitomi Kaneko, Hitoshi Hanamoto, Shin-ichi Fuchida, Hirokazu Tanaka, Satoru Kosugi, Miki Kiyota, Toshimitsu Matsui, Junya Kanda, Masato Iida, Mitsuhiro Matsuda, Nobuhiko Uoshima, Masaru Shibano, Takahiro Karasuno, Tsuneyoshi Hamada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Chihiro Shimazaki, Shosaku Nomura, Masayuki Hino, Akifumi Takaori-Kondo, Itaru Matsumura, Yuzuru Kanakura, Junya Kuroda

Summary: This study retrospectively analyzed data on the clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients. The results showed that these regimens demonstrated durable responses and manageable adverse events (AEs) in the real-world setting. However, certain poor prognostic factors were identified, such as poor performance status.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)

Article Oncology

Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial

Tsutomu Kobayashi, Kazuhito Yamamoto, Yoshitoyo Kagami, Ryunosuke Machida, Kana Miyazaki, Shigeo Nakamura, Junya Kuroda, Dai Maruyama, Hirokazu Nagai

Summary: The Kyoto Prognostic Index (KPI) shows better predictive value in the prognosis assessment of high-risk DLBCL patients compared to the conventional International Prognostic Index (IPI).

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

暂无数据